ANNUAL REPORT

2025-2026

Towards a Cancer Free World

CANCER INSTITUTE (WIA)

STATE CANCER INSTITUTE

CHENNAI, TAMIL NADU, INDIA




OUR FOUNDER

Dr. Muthulakshmi Reddy

HER VISION

State-of-the-Art Treatment for All Socio-Economic Class of Patients

Dr. S. Krishnamurthi



HIS WORDS

Service Above Self



Dr. V. Shanta

HER PASSION

Patient Comes First

Table of

Contents

1	Table of Contents	01
2	Messages & Leadership	02
3	Institute Overview	07
4	Cancer Treatment & Care	12
5	Imaging & Diagnostics	19
6	Supportive & Allied Care	21
7	Cancer Registry	25
8	Awareness & Prevention	26
9	Advanced Therapies	28
10	Academics & Training	30
11	Research & Clinical Trials	32
12	Technological Infrastructure	35
13	Donors & Volunteers	37
14	Financial Overview	38

The Cancer Institute is a unique seven-decade old institution. We as an Institution are defined not by the health of our balance sheet but by the health of our service index that is formed by the commitment and dedication to the cause of not only Cancer treatment but also prevention and eradication. Towards this end the Institute has a dedicated team of workers who have adopted a life mission of treating and battling cancer on all fronts and strive ceaselessly towards it.

We address four areas of cancer care - prevention, treatment, research and education. Each of these sectors constantly strive for perfection and excellence in their areas of endeavour. As science, research and technology supply us fresh tools to battle cancer, unfortunately these advantages are offset by increasing risks arising from constantly rising tobacco/alcohol use, poor diets lacking in nutrition either by poverty or by choice, air pollution and other environment hazards that keep throwing up fresh challenges to our work making it a journey without an end. Norman Cousins famously said, “The human body experiences a powerful gravitational pull in the direction of hope”. We as an institution strive to be the destination that pulls the hope of cancer affected patients to treatment, cure and recovery.

Every passing day we resolve to be better, more effective and more committed in our endeavors. Towards this end, the lives of our founders and those who have given much to the institute constantly guide us.

N.L. Rajah
CHAIRMAN

As the Cancer Institute completes another year of steadfast commitment to excellence in patient care, education, research, and community service, we are reminded that this year holds special significance as we commemorate the Centenary Year of Dr. V. Shanta, whose extraordinary vision, leadership, and dedication laid the foundation for the Institute's enduring legacy. Throughout the year, our academic programmes, scientific meetings, outreach initiatives, and institutional events have been dedicated to celebrating her life and reaffirming the values of compassion, equity, excellence, and service that she championed.

A major milestone during the year was the successful NABH re-accreditation, reaffirming our unwavering commitment to patient safety, quality improvement, and clinical excellence. We also achieved NABL accreditation, strengthening the quality and reliability of our diagnostic laboratories and reinforcing confidence in the standards of care delivered by the Institute. Research and academics remain cornerstones of the Institute's mission. During the year, we strengthened collaborations with leading academic and scientific institutions to foster multidisciplinary research, encourage innovation, and accelerate the translation of scientific discoveries into meaningful improvements in patient care. An important addition to research infrastructure during the year has been the establishment of a state-of-the-art Clean Room Facility to support advanced immunotherapy and cellular therapy programmes. Designed to meet stringent quality and regulatory standards, this facility will lay the foundation for the Institute's expanding immunotherapy initiatives.

The Cancer Institute continues to be recognised as a leader in oncology, with faculty members representing the Institute at major national and international oncology forums as invited speakers, moderators, panelists, guideline contributors, and members of professional societies. These contributions reflect the Institute's continued leadership in shaping cancer care, education, research, and policy.

These achievements have been made possible through the dedication of our faculty, nurses, researchers, students, technical and administrative staff, volunteers, donors, alumni, and governing bodies. Their unwavering commitment continues to strengthen our mission of delivering compassionate, affordable, and world-class cancer care. As we move forward, inspired by the legacy of Dr. V. Shanta, we remain committed to advancing innovation, strengthening research, embracing technology, and ensuring that every patient receives care of the highest quality with dignity, compassion, and hope.

Dr. Kalpana Balakrishnan

CEO & MEDICAL DIRECTOR

GOVERNING BODY

Shri N L Rajah Senior Advocate	Chairman
Dr E Hemanth Raj Vice Chairman, Cancer Institute (WIA)	Vice Chairman
Shri Srivats Ram Managing Director, Wheels India Limited	Vice Chairman
Shri R Seshasayee	Ex-Officio Chairman
Shri Vijay Sankar The SANMAR Group	Member
Shri V Venugopal Chief Financial Officer, Cancer Institute (WIA)	Secretary
Joint Secretary & Financial Adviser Govt. of India, Ministry of Health & Family Welfare	Member (Govt Official)
Director of Medical Education Directorate of Medical Education, Govt.of Tamil Nadu	Member (Govt Official)
The Director General, Indian Council of Medical Research	Member (Govt Official)
Shri C N Raghavendran C.R.Narayana Rao (Consultants) Pvt Limited	Member
Smt Girija Vaidhyanathan	Member
Dr. Krishnamurthi Sundaram Clinical Professor, Department of Otolaryngology	Member
Dr T S Ravikumar	Member
Shri Vinod Kumar Jain	Member
Dr S Suresh Director, Mediscan Systems	Member
Shri R Shankar Raman	Member
Dr Mayil Vahanan Natarajan M.N. Orthopaedic Hospital	Member
Dr Kalpana Balakrishnan CEO & Medical Director, Cancer Institute (WIA)	Member
Dr T Gnana Sagar	Member
Shri Vardhman Jain Access Healthcare Services (P) Ltd, Chennai	Member

Institutional Leadership

Dr Kalpana Balakrishnan	CEO and Medical Director, Professor - Anaesthesia, Pain Management & Palliative Medicine
Dr Arvind Krishnamurthy	Deputy Medical Director, Professor - Head of Surgical Oncology
Dr Vijayanand Pandurangan	Honorary Director - Research
Dr Swaminathan R	Associate Director, Professor - Epidemiology, Biostatistics & Cancer Registry
Smt Varalakshmi V	Associate Director (Administration)
Dr Venkatraman Radhakrishnan	Professor - Head of Medical Oncology and Paediatric Oncology
Dr Priya Iyer	Professor - Head of Radiation Oncology and In-Charge of Nursing Department
Dr Ujwala P W	Professor - Head of Gynaecological Oncology
Dr Thirumoorthi N	Associate Professor - In-Charge of Medical Gastro-entrology
Dr Punitha C	Professor - Head of Anaesthesia and Pain Management
Dr Meenakshi V V	Professor - Head of Palliative Medicine
Dr Ashok Kumar	Consultant - In-Charge of Nuclear Medicine
Dr Shirley S	Dean, Professor - Head of Oncopathology
Dr Karthigaiselvi M	Senior Consultant Radiologist - In-Charge of Radio Diagnosis and Imaging
Dr Thuthi B	Consultant - Head of Clinical Biochemistry
Dr Packia Nancy R	Assistant Professor - Head of Microbiology
Dr Malliga J S	Associate Professor - Head of Cancer Screening (Preventive Oncology)

Institutional Leadership


Dr Deepa Devi G	Assistant Professor - Head of Blood Centre
Dr Sridevi V	Professor - In-Charge of Clincial Trials Services Unit
Dr Vijayalakshmi R	Professor - Head of Cancer Biology and Molecular Diagnostics
Dr Sabitha K	Professor - Interim In-Charge of Molecular Oncology
Dr Vivekanandan N	Professor - Head of Medical Physics
Capt. Dr Muthuram	Nursing Superintendent
Dr Srinivasan Vijay	Scientist-D - Head of Physiotherapy
Dr Surendran V	Professor - Head of Psycho-Oncology
Dr Rama R	Head of Cancer Registry, Epidemiology, In-Charge of Dietetics
Dr Thendral R	Assistant Professor - In-Charge of Hospice Mahaveer Ashray
Shri Venugopal V	Chief Finance Officer - Finance and Accounts
Shri Rajshekar	General Manager - Corporate Social Responsibility and Special Projects
Shri Rajesh Krishnamurthi	Head of Information Technology
Smt Ajitha S	Chief of Human Resources and Communication
Col. Pradeep V	General Manager Operations - Administration
Srividhya Shankar	General Manager - Head of Purchase
Dr Priya Jovita Mary Martin Daniel	Professor (Medical Oncology), In-Charge of Pharmacy and Stores

About Us

The Cancer Institute (WIA) in Adyar, established in 1954 by Dr. Muthulakshmi Reddy, is a leading charitable institution in cancer care, research, and support. Evolving from a 12-bed cottage hospital to a comprehensive cancer centre with over 650 beds, it has provided accessible and affordable treatment for over seven decades. The Institute is the first comprehensive cancer centre in South India. It is a Regional Centre for Cancer Research and Treatment and is recognised as the State Cancer Institute, the apex body, providing completely free care to 23–25% of patients and subsidised treatment to 40% of patients through government and NGO support, with others paying for their care.

The Institute is a pioneer in cancer care from prevention to palliation, offering ethical and state-of-the-art multi-modality treatment. This holistic model seamlessly coordinates the patient journey within a single framework, from active prevention—via public awareness, screening camps, and vaccinations—to early cancer detection using high-precision pathology and molecular profiling. Patients receive specialised therapy alongside supportive psycho-social care, backed by a robust research division running clinical trials and a Cancer Registry for lifetime follow-up. The continuum is completed by dedicated physical rehabilitation and compassionate, cost-free hospice care at Mahaveer Ashray in Sriperumbudur.

Managing around 15,000 new cases and 1,60,000 follow-ups annually, the NABH-accredited Institute remains guided by its founding ethos of “Service above Self,” upholding a legacy of compassionate, inclusive, and high-quality cancer care for all, especially the underprivileged.



1950 ▼ 1959

1954 First comprehensive cancer centre in South India

1956 Asia's first super-voltage era with cobalt-60 teletherapy unit; first Nuclear Medical Oncology dept in India.

1957 First medical physics department in India.

1958 Pioneered combined modality for advanced oral cancers; cure rate rose from 19% to 58%.

1959 Secured concessional travel for cancer patients by rail.

1960 ▼ 1969

1960 First paediatric oncology centre in India; introduced lymphangiography for lymphoid tumour diagnosis.

1961 First rural cancer survey in India (Chengalpattu, TN).

1962 First indigenous caesium tele-curie-therapy unit (with Dr. Homi Bhabha).

1965 Recognised for Ph.D./D.Sc. in Oncological Sciences; introduced mammography for occult breast tumours in India.

1968 Designed and installed first indigenous radiotherapy simulator.

1970 ▼ 1979

1971 India's first medical oncology unit and blood component unit.

1974 Declared first "Regional Centre for Cancer Research & Treatment" in India.

1975 Installed India's first linear accelerator (gift from DANIDA).

1978 Declared "Centre of Excellence"; introduced hyperbaric oxygen therapy; introduced blood cell separator for chemo support.

1980 ▼ 1989

1981 India's first M.Sc. (Medical Physics); established Madras Metropolitan Tumour Registry.

1982 India's first oncological sciences college with M.Ch., DM, MD degrees (MCI recognised).

1985 Introduced hyperthermia in oncology; installed first ND-YAG surgical laser; performed first endoscopic laser surgery in India.

1987 First limb conservation surgery with custom prosthesis for bone cancer in India.

1990 ▼ 1999

1995 First intra-operative radiotherapy (IORT) facility; installed first indigenous brachytherapy unit (CITRON).

1999 15th Asian & Pacific Cancer Conference (APCC) held.

2000 ▼ 2009

2002 Started first hereditary cancer detection/prevention program; launched WHO Tobacco Cessation Clinic.

2004 Developed and tested dendritic cell vaccine for cervical cancer (Phase 1).

2006 Established National Tumour Bank; started telemedicine with six nodal centres.

2007 Established Centre of Excellence for Molecular Oncology.

2008 Installed India's first Rapid Arc Therapy; first radiotherapy simulator with cone beam facility.

2010 ▼ 2019

2013 Diamond Jubilee inaugurated by CM Dr. J. Jayalalithaa; launched Tamil Nadu Cancer Registry Project, MRI, True Beam Radiotherapy.

2016 Dr. V. Shanta received Padma Vibhushan.

2017 Established Mahaveer Ashray Palliative Care Centre (free care).

2018 PM Narendra Modi inaugurated new patient care facilities, Mahaveer Ashray, and L&T Illam.

2020 ▼ PRESENT

2020 Maintained uninterrupted treatment during COVID-19.

2024 Joined India's elite with exclusive Endoscopy Suite and Cath Lab.

2025 Introduction of HIS and HRMS Hospital Information System and Human Resource Management System

2025 Inauguration of New Academic Block and Auditorium

2025-26 Year in Numbers

650+ Beds

1,200+ Staff

1,96,751
Cases Registered

12,258
New Patients Registered

78
Bone Marrow Transplants

1 in 8
patients treated from outside Tamil Nadu.

91
Research Publications

9,841
patients supported through palliative care.

27,633
people screened through district camps across Tamil Nadu.

>2,00,000
people reached through the Cancer Awareness Bus since 2021

~65%
of patients receive either completely free or subsidised care.

6,711 Blood and Component Donors

139 Students Graduated

>2,000
Individual and Institutional Donors

2,654
Major Oncological Surgeries

4,173
Endoscopic Procedures

52,712
Radiation Treatment sessions

21,472
Chemotherapy Sessions.

Mr. S. Bashyam was diagnosed with cancer in 2013 when he noticed a small white dot on his tongue. When he first heard the news, he believed his countdown had begun, and fear gripped his entire family. Through his doubts and frustration, he stayed strong for his loved ones. He chose hope over despair, stayed motivated, and became their source of courage. Following extensive evaluations, he underwent surgery in early 2014 and completed 30 sessions of radiation therapy. Through his visits, he saw multiple patients of all ages come in for check-ups. It reminded him that he was not alone in his fight. With every interaction, his confidence grew as he witnessed the others bravely undergoing treatment, and he placed his trust in his doctors. Today, after 35 years of service at the Ahobila Madam, he enjoys his voluntary retirement peacefully in Chennai with his family. He truly cherishes life.

A Master's graduate in Sanskrit, he continues to share strength by reciting the Ramayanam in homes that invite him. He stands as a reminder that faith, early action, and trust in treatment can help overcome cancer.



Mr. S. Bashyam

A Destination for Cancer Care

Across India and the Globe

Regionwise distribution of newly registered patients



Tamil Nadu
10,771



Karnataka
79



Andhra Pradesh &
Telangana
772




Kerala
91



Assam
47



Puducherry
112



Rest of India
349



Outside India
37



Medical Oncology

At the Cancer Institute (WIA), our systemic therapy services deliver advanced, evidence-based chemotherapy, precision oncology including immunotherapy, targeted therapy, bone marrow transplants and CAR-T cellular therapies across adult and paediatric malignancies. Operating some of the highest-volume infusion units in the region, our clinical teams combine rigorous clinical protocols with dedicated patient-centered care to manage malignancies at every stage.





Key Highlights


78
Bone Marrow Transplants

21,472
Chemotherapy Infusions


8,360
Paediatric Chemotherapy Preparations

2
CAR-T Treatments

Chemotherapy Sessions



Bone Marrow Transplants



Surgical Oncology

Surgical Oncology at the Cancer Institute (WIA), Chennai, remains a cornerstone of the Institute's comprehensive cancer care programme. The department specialises in the surgical management of all solid tumours, employing advanced precision techniques—including laparoscopic and robotic surgery—wherever clinically appropriate. The emphasis is on complete tumour removal while carefully preserving form and function, thereby optimising quality of life for patients.

Building on its established legacy, the department continues to advance both clinical excellence and education in oncologic surgery, reinforcing the Institute's dedication to high-quality, holistic cancer care.


Key Highlights

2,654
Major Surgeries
(2025–26)

4,173
Endoscopic Procedures
(2025–26)

470+
Robotic Surgeries
(Since 2021)

Major Surgeries by Specialty



22.9%	Head & Neck	607
21.3%	Breast	566
14.2%	Gastrointestinal	377
14.5%	Gynaecology	386
10.8%	Musculoskeletal	286
9.6%	Urology	255
3.7%	Neurosurgery	97
3%	Thoracic	80

Radiation Oncology

Cancer Institute (WIA) provides comprehensive radiation therapy across a full spectrum of cancer sites, using advanced technology and precision treatment protocols. In 2025-26, the institute treated 2,672 new patients on external beam therapy — a 15% increase over the previous year — and delivered a total of 52,712 treatments and 2,19,559 fields across all modalities.

The institute offers a range of specialised techniques including Stereotactic Radiotherapy (SRT), Stereotactic Body Radiotherapy (SBRT), Total Body Irradiation (TBI), Total Skin Electron Therapy (TSET), and Deep Inspiration Breath Hold (DIBH). The acquisition of the Varian Halcyon linear accelerator this year has further expanded the institute's capacity for faster and more accurate delivery of complex radiotherapy.



Nuclear Medicine

Nuclear medicine utilises targeted radioactive compounds to evaluate physiological processes at a molecular level, enabling early-stage cancer diagnosis and therapy. The institute provides both traditional radionucleide therapy as well as targeted nuclear medicine therapies that are more precise and have minimal side effects.

Radionucleide Procedures (2025-26)

92 Conventional Therapy

56 Advanced Targeted Therapy

Oncology Nursing

Our nursing services represent the compassionate, evidence-based heart of our multidisciplinary oncology care, supporting patients across the entire cancer care continuum. With a strong clinical team of 460 dedicated nurses, our nursing staff delivers highly specialised oncology care across outpatient clinics, in-patient wards, operating theatres, day care treatment centres, intensive care units, and our Mahaveer Ashray palliative hospice centre.


Regional Capacity Building Hub

Under ECHO India's "Cancer Mukt Bharat" project—which has trained over 600 nurses nationwide—the Cancer Institute (WIA) serves as the central regional HUB for an advanced capacity-building program. The Institute equips nursing professionals from district, tertiary government, and private hospitals across Tamil Nadu with specialised skills in cervical and breast cancer detection, prevention, and treatment. This initiative plays a pivotal role in closing the gap in regional oncology care, driving early detection and timely intervention.



Paediatric Oncology

The Paediatric Division of the Institute delivers comprehensive, protocol-based care to children and adolescents undergoing cancer treatment. Operating within the child-friendly Mahesh Memorial Paediatric Oncology Centre, the division integrates advanced multi-modal therapies, cellular transplants, clinical trials, and dedicated play therapy. This clinical framework is reinforced by active support networks that address the physical, psychological, and nutritional needs of patients and their families throughout the treatment and survivorship continuum.



Ms. Satyanarayana, a leukaemia survivor (diagnosed in 2003 in Visakhapatnam), began her journey through recovery at just four years of age. Too young to understand the disease, she underwent years of treatment and regular follow-ups, supported by the kindness of an unknown benefactor. At first, she didn't really understand anything about her illness. At around 9th grade, when she stopped taking her medication, she made a decision to view herself the same as her peers. She held herself up to the standards of anybody else in her class and refused to fall back. While growing up with an illness she couldn't fully comprehend, she chose to define herself as a perfectly normal person, even through the medications and treatment. She believed in her own strength and in living life without fear. As she matured, she came to truly understand the journey that shaped her resilience. Today, she is a Bachelor of Pharmacy graduate and works as a clinical research coordinator at Nizam's Institute of Medical Sciences, Hyderabad, Telangana, while still continuing her yearly preventive check-ups.

Her story reminds us that with early care, inner strength, and hope, cancer is not the end of life; it is the beginning of a stronger one.



Ms. Satyanarayana

Anaesthesia and Pain Management

The Cancer Institute (WIA) delivers highly integrated, comprehensive perioperative care, specialized onco-anaesthesia, and advanced acute and chronic pain management services across all oncological specialties. A dedicated team of clinical faculty, senior residents, medical officers, and specialized technologists works collectively to enhance patient safety, clinical outcomes, and comfort throughout the therapeutic journey.

5,042 Anaesthesia cases

6,984 PAC Visits

1524 Acute Pain Cases

2410 New Patients

7012 OPD Consults

417 Home visits

Palliative Care

The institute delivers compassionate, multidisciplinary palliative care and advanced symptom management for patients with advanced cancers. A dedicated team of clinicians, specialized nurses, counsellors, and volunteers provides holistic physical, emotional, and spiritual support. This comfort-oriented care extends from acute hospital divisions to cost-free, dignity-focused hospice services.

Hospice Care – Mahaveer Ashray

Mahaveer Ashray, the hospice of Adyar Cancer Institute, provides compassionate and dignified end-of-life care. The art gallery - Wings of Expression - inaugurated on 15 November 2025, showcases the artwork of patients — a reflection of their creativity, experiences, and personal journeys, and is the first of its kind in an Indian hospice.

As Mahaveer Ashray steps into its 10th year, its commitment to compassionate, dignified end-of-life care remains steadfast.

10TH YEAR

2342 Patients Supported in Hospice





Precision Diagnostics

The Cancer Institute (WIA) drives a highly integrated, cutting-edge clinical testing and translational research framework that unites molecular oncology, cancer genomics, clinical microbiology, and high-throughput biochemistry. By pairing advanced laboratory automation with clinical vigilance, the Institute's state-of-the-art facilities deliver rapid, evidence-based diagnostics and care.

Key Highlights

22681
Molecular diagnostic tests

1121
Next generation sequencing tests

>10 LAKH
Clinical Biochemistry samples processed

29058
Microbiology samples tested

1186
BCR-ABL tests for detecting Chronic Myeloid Lukemia

Blood Centre

The Institute has a dedicated Blood Centre which supports safe, voluntary blood donations, specialized cell separations, and advanced therapeutic apheresis to serve the complex transfusion and transplantation requirements of the Institute's clinical departments

5859 Whole Blood Donations

789 Platelet Donations

63 Granulocyte Donations

15054 Total Transfusions





Radiology & Imaging

Radio-diagnosis and Imaging Sciences serves as a vital diagnostic and interventional pillar of the institute, delivering high-resolution imaging and supporting targeted image-guided therapies.

29,171	549	5,874	18,050	15,116	3,936
Digital X-rays	C-ARM & special procedures	Mammogram	Ultrasound	CT	MRI

Onco-Pathology

The Cancer Institute (WIA), Adyar, provides comprehensive oncopathology services, processing an extraordinary volume of specimens across histopathology, cytopathology, haematopathology, and clinical pathology, delivering precise insights critical for staging, therapy selection, and prognostication across all clinical specialties.

Specimens Processed (2025-26)

24,526	12,626	9,614
Histopathology	Cytopathology	Haematopathology



Supportive & Allied Care

Limb Salvage Surgery

Limb salvage surgery offers patients with extremity sarcomas the possibility of effective cancer control while preserving limb function and quality of life. With careful imaging, multidisciplinary planning, wide tumour clearance, and advanced reconstruction, limb preservation can be achieved without compromising oncological safety. Our approach combines surgical expertise, reconstruction, rehabilitation, and long-term follow-up to help patients return to meaningful function.

This year we completed limb salvage surgery for 37 patients with bone sarcoma and 37 patients with soft tissue sarcoma.

Prostheses

A total of **338 patients received** prostheses, including breast prostheses, wigs and stoma bags.

75 External Breast Prostheses

60 Natural Hair Wigs


203 Stoma Bags for Colorectal Cancer Patients

After Completion Therapy

The After Completion Therapy (ACT) Clinic supports cancer survivors as they transition from active clinical treatment back into daily life. Key aspects of its work include

- Survivorship Care Plans
- Paediatric Neurocognitive Monitoring
- Reintegration Counseling
- Peer Support Groups

Visits to the ACT Clinic (2025-26)



- 700 Follow Up
- 299 AYA
- 221 Paediatric

Physiotherapy

Our physiotherapy and rehabilitation services deliver evidence-based oncological rehabilitation to restore physical function and enhance quality of life across the cancer care continuum. The institute provides a treatment called Complete Decongestive Therapy (CDT) to relieve lymphoedema which can be a side effect for many patients. This year 17 patients received these multilayer bandaging kits to help improve their quality of life.



Complete Decongestive Therapy (CDT) for Lymphoedema

Dharmasala



Our compassionate care extends beyond diagnosis and treatment. Through the Dharmasala, patients and their attenders are provided free food and accommodation, helping families stay together and reducing the financial burden that often accompanies prolonged cancer care. This initiative reflects the Institute's longstanding philosophy that caring for a person with cancer also means caring for the family that stands beside them.

Vishranthi Graha

Established with the generous support of the Singhvi Charitable Trust, Vishranthi Graha is a dedicated patient waiting lounge. Every day, hundreds of patients and attenders travel to Chennai for cancer care. Vishranthi Graha provides them with a safe, clean and comfortable space to rest and refresh, with convenient access to essential facilities, including the pharmacies, ATM, bank, cafeteria etc.

For patients and attenders

Safe and Clean

Space to rest and refresh

Alternative Livelihoods for Women Rolling Beedis

To transition women from the toxic hazards of manual beedi rolling, the Cancer Institute (WIA) and the HCL Foundation launched a targeted alternative livelihood program. Surveys revealed that 78% suffered from occupational illnesses and 80.4% desired to change careers. In response, the Institute initiated free, hands-on training in tailoring, handicrafts, and wig-making; a follow-up assessment of 148 trainees documented 106 women completely stopping all beedi-rolling activities, an outstanding 72% success rate.



"Switching to tailoring has transformed my life. Not only am I healthier, but I also feel more secure about my children's future. I am grateful for the training program and hope more women like me find a way out of beedi rolling."

— Mrs. Essakiammal

"I used to roll beedis, which I know contributed to people getting cancer. It was a job that harmed not only me but also others. Now, I am proud to make wigs for cancer patients. I feel like I am finally making a positive difference in people's lives. It's truly rewarding to know that my work brings joy to someone who is fighting cancer."

— Mrs. Malathi



Quality Control

The Institute's Quality Control strengthened patient safety, quality improvement and NABH compliance during 2025–26.

6 Major internal audits, including 2 Hospital-Wide Audits	**32** Hospital-wide and 5 department-specific quality indicators monitored
18 Clinical care pathways/protocols developed or reviewed	**3** Key staff awareness initiatives conducted
QR-based patient feedback introduced	

Prashanth P.N. was diagnosed with Acute Lymphoblastic Leukaemia in 2014, just after completing his engineering degree, at the threshold of his working life. Given this news at the cusp of starting his life as an adult, fear and uncertainty gripped him. His journey pushed him both mentally and physically. When he was confined to his hospital bed, the walls became a place of quiet lessons, where shared stories and fragile hopes from fellow patients offered him “strength, hope, and motivation.” Having people around him who shared the same suffering showed him that they were in this together and that recovery doesn’t happen in a vacuum. Inspired by his found community, illness transformed into resilience; from pause came purpose. After recovery, he rebuilt himself by learning new skills across diverse fields. After completing his treatment in 2017, he was drawn towards understanding the human heart and mind. He returned to study psychology, completing both a B.Sc. and M.Sc. Today, he is involved in business, continuing his studies, and working as a school administrator, carrying a life shaped by endurance, compassion, and unwavering hope.

“My life journey has taught me resilience, adaptability, and the importance of never giving up.”



Prashanth P.N.

Tracking The Disease: Cancer Registry

At the Cancer Institute (WIA), our analytical core translates seventy years of longitudinal surveillance into proactive, state-level cancer control. This framework is anchored in historical milestones, from establishing India's first and longest-running hospital-based cancer registry in 1954 to operating the massive, statewide Tamil Nadu Cancer Registry Project (TNCRP). By bridging decades of patient-tracking history with modern digital tools, we continue to turn statistical data into active, life-saving public health interventions.

Lifetime Follow-Up

The Cancer Institute (WIA) employs a highly systematic, dual-method lifetime follow-up system to track the long-term clinical progression and vital status of all registered patients. Under this framework, passive follow-up during scheduled patient reviews and active follow-up with dedicated social investigators serve as a clinical reminder for survivors and provide crucial statistical data on cancer incidence, treatment and survival outcomes.

Survival trends over three decades show a steady improvement across all cancers, with significant improvements in breast cancer, ovarian cancer and acute lymphoid lukaemia (ALL) indicating advances in diagnosis and treatment.

5-Year Survival Rate (1991-2018)

30.3% ▸ 70.2%
Acute Lymphoid Leukaemia (ALL)

56.3% ▸ 72.4%
Breast Cancer

35.5% ▸ 51.2%
Ovarian Cancer

Launch of TN-CReSt Web Portal

Launched on March 11, 2026, the Tamil Nadu – Cancer Registry Statistics (TN-CReSt) web portal (https://tn-crest.cancerinstitutewia.in/) is India's first-of-its-kind online analytics tool to grant universal public access to state-level cancer incidence data. Built by the institute with funding from the Bank of New York (BNY), the portal is powered entirely by the collaborative Tamil Nadu Cancer Registry Program (TNCRP).



Prevention Through Awareness and Action

Our focus on cancer awareness and prevention is a core, foundational pillar of our institutional mission. From our inception, our leadership recognised that achieving a truly cancer-free world requires looking beyond the clinic walls to intercept the disease at its earliest, most treatable stages. Through community advocacy and awareness programmes, mobile clinics, and screening camps, the Institute continues to translate our founders' visionary ideals into an active, everyday public health reality.

Tobacco Cessation

Tobacco consumption is the single most significant modifiable risk factor in cancer prevention efforts and the Institute operates a highly active multi-pronged Tobacco Control portfolio. This integrates clinical tobacco cessation services, intensive educational campaigns, state-level youth advocacy, and pioneering alternative livelihood interventions.

Rallies & Advocacy	Cancer Screenings	School Safety Programmes

521 Free-of-cost tobacco cessation support provided to individuals and caregivers


Statewide HPV Vaccination for School Girls

Supported by a grant from the Union for International Cancer Control (UICC), the Institute developed actionable strategies and completed health system readiness assessments for HPV vaccination across four pilot districts: Dharmapuri, Thiruvannamalai, Perambalur, and Ariyalur. This groundwork directly supported the Government of Tamil Nadu in launching its official, school-based HPV vaccination programme for schoolgirls in January 2026. The pilot was a major success, achieving 81% coverage in six weeks, and was officially scaled up statewide supported by a Government of India grant.



District Cancer Screening Programs

Since 2008, the institute has been conducting early screening and intervention programs. The initiative, which started in Chennai now spans six districts across the state including Chennai, Viluppuram, Tiruvallur (Gummidipoondi), Pudukkottai, Tiruvannamalai, and Sivagangai (Devakkottai). In 2025-26, a total of 2,205 men and 25,428 women were screened and pre-cancer or cancer was detected in 81 people.



Chennai
Men 31 | Women 4,575
Abnormal Findings 8

Tiruvallur (Gummidipoondi)
Men 296 | Women 4,174
Abnormal Findings 12

Tiruvannamalai
Men 153 | Women 4,489
Abnormal Findings 21

Villupuram
Men 675 | Women 4,381
Abnormal Findings 19

Pudukkottai
Men 647 | Women 4,019
Abnormal Findings 11

Sivagangai (Devakkottai)
Men 403 | Women 3,790
Abnormal Findings 10

Viluppuram Mammogram Launch

On October 8, 2025, a state-of-the-art digital mammography unit was launched at the Villupuram centre, supported by the Rotary Club of Madras and Access Healthcare. This provides early screening access to over 4.5 lakh women residing across Villupuram, Cuddalore, and the Ulundurpettai taluk of Kallakurichi districts.




Advanced Therapies

Cancer Institute (WIA) continues to expand access to advanced therapies at the forefront of modern oncology. These programmes bring together cellular science, molecular targeting, robotic technology and multidisciplinary expertise to treat complex cancers with greater precision and personalisation. Providing these therapies requires significant multidisciplinary clinical expertise, support and infrastructure.

CAR-T Cell Therapy

CAR-T cell therapy represents a major advance in personalised cancer treatment. Often described as a form of "living medicine," it uses a patient's own immune cells, which are genetically modified to recognise cancer cells. The reprogrammed cells are infused back into the patient, where they can identify and attack the disease.

This highly specialised therapy offers a new treatment pathway for certain patients with blood cancers. Cancer Institute (WIA) pioneered CAR-T therapy in South India—first offering it in October 2020 and delivering it outside a clinical trial in May 2022. In April 2024, it became the first centre in Tamil Nadu to administer NexCAR19, India's indigenously developed CAR-T product.




2 CAR-T cell therapy procedures completed this year

Bone Marrow Transplantation

Bone marrow transplantation is an advanced form of cellular therapy that restores healthy blood formation after diseased or damaged stem cells have been eliminated. It can also harness the donor immune system to recognise and attack residual cancer cells. The Institute's multidisciplinary programme supports both adults and children.

Every transplant requires carefully coordinated donor selection, conditioning therapy, stem-cell processing, infection prevention and long-term monitoring—supported by expertise across haematology, transfusion medicine, intensive care and laboratory services.




78 transplants completed

Robotic Surgery


Robotic-assisted surgery brings advanced digital technology into the operating theatre. The fourth-generation Da Vinci Xi system provides surgeons with magnified three-dimensional vision and highly articulated instruments capable of precise movement within confined anatomical spaces.

This enhanced control supports complex cancer operations through smaller incisions, potentially reducing blood loss and postoperative discomfort while enabling earlier recovery. Supported by a ₹120 crore grant, the technology is used across the Institute's major oncology specialties, including robotic oesophagectomy and trans-oral robotic surgery.



470+ robotic-assisted surgeries completed since January 2021

Targeted Radionuclide Therapy



Targeted radionuclide therapy is an emerging precision-oncology approach that treats cancer from within the body. Specialised radiopharmaceuticals travel through the bloodstream, recognise molecular features expressed by tumour cells and deliver therapeutic radiation directly to disease sites. This approach can treat cancer deposits in multiple locations while preserving healthy tissue.

45 Lu-177 DOTATATE procedures for neuroendocrine tumours

6 Lu-177 PSMA procedures for advanced prostate cancer

1 Lu-177 EDTMP procedure for metastatic bone pain

1 Sm-153 EDTMP procedure for metastatic bone pain

Academics & Training


The Cancer Institute (WIA) demonstrates an unwavering commitment to oncology training and education through its comprehensive academic curriculum. Under the guidance of the college administration, the institution coordinates a diverse portfolio of undergraduate, postgraduate, and doctoral programs.

The Institute offers an array of National Medical Commission (NMC) recognised postgraduate medical specialties—including M.D. Radiation Oncology, D.M. Medical Oncology, D.M. Onco-Pathology, and M.Ch. Surgical Oncology—all affiliated with The Tamil Nadu Dr. M.G.R. Medical University.

Expanding its clinical specialties, the college provides National Board of Examinations in Medical Sciences (NBEMS) recognised programs, including D.N.B. in Palliative Medicine, D.N.B. in Radio Diagnosis, and F.N.B. Onco-Anaesthesia. It also offers advanced clinical training through recognised fellowships such as Onco-Imaging, Breast Imaging, and Onco-Anaesthesia and Perioperative Medicine.


Allied health education remains a vital area of growth, featuring four B.Sc. undergraduate specialties and a postgraduate M.Sc. in Medical Physics. Furthermore, the Institute's doctoral research program, recognised by the University of Madras and Anna University, fosters scientific discovery across Molecular Oncology, Psycho-Oncology, Cancer Biology & Molecular Diagnostics, and Medical Physics. Completing this educational ecosystem are our regular, highly impactful certificate programs in Essentials of Palliative Care and Tobacco Cessation.

Graduates by Category (2025-26)



- PG Medical Specialties 23%
- PhD 1.4%
- PG Allied Healthcare 22.3%
- UG Allied Healthcare 18%
- Certificate 35 .3%

Graduation Trends (2022-2026)



For the period of **April 2025 to March 2026**, the Cancer Institute (WIA) awarded **11 best outgoing students:**



Dr. Hanumitha R	D.M. Medical Oncology
Dr. Sneha K	D.M. Oncopathology
Dr. Gurushankari B	M.Ch. Surgical Oncology
Dr. Pravin Sankar P R	FNB Onco-Anaesthesia
Dr. Bhavani V	M.D. Radiation Oncology
Dr. Jefrilla Nancy J	DNB Palliative Medicine
Ms. Kaviya Priya V	M.Sc Radiotherapy Technology
Ms. Aarthi P	B.Sc Radiotherapy Technology
Ms. Sangeetha Vani S	B.Sc Radiography & Imaging Technology
Ms. Sabitha R	B.Sc Operation Theatre & Anaesthesia Technology
Ms. Aishwarya T	B.Sc Nuclear Medicine Technology

New Auditorium

This year, a new auditorium was inaugurated in the new academic block located on the 1st floor of the Diagnostic Complex, also known as the Bhagavan Adinath Jain Complex. The construction of the state-of-the-art facility with a large seating capacity was made possible by the generous support of Durr India Private Limited.





Clinical Trials From Bench to Bedside

The Cancer Institute (WIA) is one of the nation's leading oncology clinical research hubs, and is a part of the National Cancer Grid Clinical Trial Network. The Clinical Trials Services Unit (CTSU) governs all clinical trial activities across the institute, ensuring the highest standards of ethics and data integrity. It houses a dedicated facility with a 30-seat workspace, an 8-bed trial ward, a research pharmacy, a secured archival room, and a participant consenting room. All operations strictly adhere to Good Clinical Practice (GCP) guidelines and international standards.

Clinical Trials 2025 -26

36 Ongoing Trials

8 Completed Trials



Today's Research, Tomorrow's Cure

Over the years, the Cancer Institute (WIA) has contributed a lot to cancer research in India. During this time, the Institute has cared for patients with dignity and equity, conducted clinical trials, and developed a foundation in translational research.Today, the research helps in building the knowledge needed to improve cancer prevention, diagnosis and treatment, in order to provide better care and possible cures in the future.

Research Publications

The Cancer Institute (WIA) continues to stand as one of India's premier centres for oncological discovery, consistently sharing its clinical insights and basic science breakthroughs with the global medical community. By publishing extensive research in leading national and international peer-reviewed journals, our experts advance and inform the standard of care in oncology.

Peer Reviewed Publications

42 National Journals

49 International Journals



Research Grants

1. HBCR-RCC – Hospital Based Cancer Registry in Regional Cancer Centres (National Cancer Registry Programme (NCRP), Indian Council of Medical Research (ICMR))
2. Madras Metropolitan Tumour Registry (MMTR) (NCRP of ICMR)
3. Tamil Nadu Cancer Registry Programme (TNCRP) (Collaboration with Department of Health and Family Welfare, Government of Tamil Nadu)
4. Enriching Cancer Data in Tamil Nadu State in South India (International Agency for Research on Cancer (IARC))
5. ACCI Project – Access Cancer Care India (Kings College London (KCL) through the International Agency for Research on Cancer (IARC))
6. Linkage of Nationwide HPV Vaccine Cohort with Population-Based Cancer Registries in India (International Agency for Research on Cancer (IARC))
7. Bank of New York (BNY) Grant – Identification of Prognostic Biomarkers for Oral and Oropharyngeal Cancer (Bank of New York (BNY))
8. Population-Based Childhood Cancer Registry (PBCCR) – Chennai
9. UICC Grant – "Vaccinate for the Future…" (Union for International Cancer Control (UICC))
10. Bank of New York (BNY) Grant – Tamil Nadu Cancer Registry Statistics (TN-CReSt) Web Portal (Bank of New York (BNY))
11. ICMR-NHRP Project – Implementation Research to Enhance Screening, Early Diagnosis and Initiation of Treatment for Oral, Breast and Cervical Cancer in Selected Districts of India National Health Research Priority project (ICMR)
12. DHR-ICMR Advance Molecular Oncology Diagnostic Services (DIAMOnDS) Project (Department of Health Research (DHR), ICMR)
13. Prediction of T Cell and B Cell Epitopes for AKAP3 (Cancer Testis Antigen) by Computational and Experimental Analysis (Terry Fox Foundation)
14. Identification of Tumor Suppressor Kinases Inactivation by Pathogenic Genetic Variants and Analysis of Consequential Dysregulated Signalling in Gastric Cancer (DST-SERB, DST-WISE)
15. Identification and Validation of Alternative Therapeutic Targets in Ewing Sarcoma (SERB)
16. Screening and Identification of Hormone Receptor Bound Tissue-Specific Co-Regulator Complex Proteins as Novel Therapeutic Targets and Subsequent Drug Repurposing in Cervical Cancer (ICMR)
17. Screening, Identification and Validation of BBB Permeable Small Molecules with Predictive Drug Response Against EGFRvIII Positive Glioblastoma (Terry Fox Foundation)
18. Design of Peptide-Based Checkpoint Inhibitors for Affordable Targeted Immuno-Combination Therapy (ICMR)
19. OPTIMISTICC (Opportunity To Investigate the Microbiome's Impact on Science and Treatment In Colorectal Cancer) – Large Bowel Microbiome Disease Network, Phase 2 (Cancer Research UK)
20. PEACOCC (Pan-India Early-Onset Colorectal Cancer Consortium)
21. MolOnco-DnT-CenTr Translational Centre for Diagnostic and Therapeutic Technologies in Molecular Oncology (ICMR-CAR)
22. Genomic and Whole Transcriptomic Characterisation of Left and Right Sided Colon Cancer (Science and Engineering Research Board, DST (Core Research Grant))
23. ID-PPP-OTN : Infrastructure and Development of Technologies for Pre-Clinical Evaluation, Product Establishment and Platform Integration for Onco-Theranostic Applications (SERB)
24. InPOG-HL-19-03 Response-Adapted Management of Childhood Classical Hodgkin Lymphoma (cHL) and Early Response Assessment by PET-CT
25. CC-Bridge – Childhood Cancers Budgeting Rapidly to Incorporate Disadvantaged Groups for Equity
26. PASHA 2025–2026 Cohort Feasibility and Impact of Implementation of Paediatric Early Warning System (PEWS) in the Paediatric Oncology Unit of a Tertiary Care Cancer Center

27. Validation of the SNPs involved in promoting Genetic susceptibility to Oral Cancer among long term tobacco chewers identified in the north-eastern and southern Indian population (DBT)
28. Relevance of Human papillomavirus infection to the carcinogenesis of the oral tongue cancers (Tamil Nadu Dr. MGR Medical University)
29. Evaluation of BRAF V600E mutations in papillary thyroid cancers - a clinician's perspective (ICON)
30. Companion diagnostics for detection of EML4-ALK translocation in non-small cell lung cancers (Pfizer IIR)
31. Study of BRAF mutations and promoter methylation in papillary thyroid cancers (BRNS)
32. A phase III, double-blind, placebo controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumors (ADD-ASPIRIN) (MRC UK)
33. A feasibility study for assessing novel salivary diagnostics and epidemiological profile for screening and detection of early oral cancer and precancer (PHFI, India)
34. Phase IIb/III study to determine efficacy of curcumin and metformin to reduce the incidence of second primary tumors of aero-digestive tract in patients with history of head and neck squamous cell carcinoma (SPT Trial) (National Cancer Grid, India)
35. A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in previously treated patients with locally advanced or metastatic, radio-active iodine refractory BRAFV600E mutation-positive Differentiated Thyroid Cancer (Novartis)
36. Design and evaluation of the diagnostic accuracy of a bimodal multispectral and high-resolution microendoscopy imaging of premalignant oral lesion in comparison to visual inspection in screen-positive patients (ICMR)
37. Intrinsic subtyping using high throughput quantitative gene expression profiling and SERS based approach to predict pathological complete response in triple-negative breast cancer patients (TNBC) (ICMR)
38. Evaluating diet, essential minerals, oral bacteria, and body fat for head and neck cancer treatment: A prospective study in two large cancer centres in India (ICMR)
39. Oral microbiota and early oral cancer (MICRO-ORAL): A pilot study to standardize sequencing of oral microbiota in saliva samples (IIR)

"Mr. Prabakaran, from Sakkottai village in Thanjavur district, was diagnosed with cancer at the age of 19 in 2016 after noticing a small lump on his neck. He was told that he might have only 3 more months left. With the help of his doctors and counsellors, he started his treatment. While his peers were planning their futures and chasing their dreams, he fought through intense anger, fear, and frustration while grappling with the side effects of his medications. Through chemotherapy, major surgery, and emotional challenges, the comfort and support offered by his loved ones was what gave him strength. After completing his treatment, he returned to college, earned his degree, and went on to build a stable professional life while also completing an additional degree. Today, he continues regular preventive follow-ups and lives with confidence and gratitude, proving that courage and belief can turn adversity into triumph.

Let us defeat cancer! While we are all alive!"



Mr. Prabakaran A

Technological Infrastructure: Powering Care and Cure

The Cancer Institute (WIA) continues to invest in advanced equipment across its clinical departments. In 2025–26, the institute commissioned six new systems spanning surgical oncology, radiation therapy, neurosurgery, anaesthesia and molecular diagnostics — strengthening its capacity to deliver precise, safe, and effective cancer care.

RUBINA LAPAROSCOPY SYSTEM

The Rubina Laparoscopy System provides high-definition imaging and visualisation during laparoscopic procedures, enabling surgeons to perform minimally invasive surgeries with greater clarity and control. The system supports a range of abdominal and pelvic cancer surgeries, reducing patient recovery time and surgical risk.





HALCYON LINEAR ACCELERATOR (LINAC)

The Halcyon Linear Accelerator has been commissioned in the Radiation Oncology Department. It delivers fast, precise radiation therapy to cancer patients using advanced beam shaping technology. The system is designed for high patient throughput without compromising treatment accuracy, supporting a broad range of cancer sites with streamlined workflows and reduced treatment times.

NEURO NAVIGATION SYSTEM

The Neuro Navigation System is now in use in the Operation Theatre to assist with complex neurosurgical procedures. It provides real-time, image-guided navigation during surgery, allowing surgeons to accurately locate and target the area of interest. The system improves surgical precision in procedures involving the brain and spine, where accuracy is critical to patient outcomes.





ANAESTHESIA WORKSTATION

The new Anaesthesia Workstation is deployed in the Operation Theatre. It provides controlled delivery of anaesthetic agents and continuous monitoring of patient parameters throughout surgical procedures. The system supports safe anaesthesia management across a wide range of cancer surgeries, with integrated monitoring that assists the clinical team in maintaining patient stability.

AUTOMATED HPV SCREENING

The Abbott Alinity m System was installed in October 2025. This fully automated, high-throughput molecular diagnostic platform was integrated into the Institute's HPV Centralised Facility— India's first centralised facility of its kind that has since screened more than 35,000 women. The new system scales up the precision, volume, and reliability of HPV DNA testing, boosting the Institute's extensive community-based cervical cancer screening programs.





HIGH SPEED NEXT-GEN SEQUENCING

In February 2026, the institute added the Genexus Integrated Sequencer at the Next Generation Sequencing Facility. This state-of-the-art, fully automated platform represents a monumental leap, delivering clinical Next-Generation Sequencing (NGS) results within just 48 hours, significantly cutting down traditional diagnostic wait times. This enables clinicians to make rapid, personalised, and evidence-guided treatment decisions and also drives forward the Institute's cancer genomics research.

IT & DIGITAL INFRASTRUCTURE: THE TRANSITION TO OHUM

The institute successfully executed a full transition to the OHUM Hospital Information System. A single, unified digital backbone, OHUM seamlessly integrates every stage of the patient journey, connecting outpatient registration, diagnostics, treatment planning, and billing with discharge summaries and long-term follow-up care. This transition provides clinical teams with secure, round-the-clock access to real-time patient data, reduces manual documentation errors, and streamlines coordination across drug inventories, financial systems, and tumou r registries. Through this rapid, coordinated deployment, the Institute has taken a defining step forward in delivering a highly efficient, fully digitised, and deeply patient-centric model of oncology care.



Donors & Volunteers

The Cancer Institute (WIA) stands as a monument to collective compassion. Our mission to provide world-class, equitable oncology care is made possible through an extraordinary ecosystem of giving.

With over 2,000 individual and institutional donors supporting our mission this year, every contribution directly sustains our daily clinical, research, and patient care operations. We express our profound gratitude to our grassroots supporters and to our corporate and trust partners whose vital investments enable us to continually advance medical science and upgrade our healthcare infrastructure.

MAJOR DONORS


- Sundaram Fasteners Limited
- The Clearing Corporation of India Ltd
- Cancer Institute (WIA) Foundation Inc
- Housing and Urban Development Corporation Ltd
- Sundaram Finance Limited
- LIC Golden Jubilee Foundation
- Spincotech Pvt Ltd
- Larsen & Toubro Limited
- LIC Housing Finance Ltd
- Siemens Healthcare Private Limited
- RBL Bank Limited
- Super Auto Forge Private Limited
- Dürr India Pvt Ltd
- R N-B D G Foundation
- Vara Future LLP
- The Sathyanarayana Charitable Trust
- Ramasubbu K
- Will of Mrs Sukunthavalli
- HDFC ERGO General Insurance Co., Ltd
- Axles India Limited
- BNY Mellon Technology Private Limited
- Hema Ramasubbu
- West Pharmaceutical Packaging India Pvt Ltd
- Bagchi Foundation
- Yanfeng India Automotive Interior Systems Pvt Ltd
- K L A Tencor Software India Pvt Ltd
- Sri Balaha Chemicals Private Limited
- STCI Finance Limited
- Dormakaba India Private Limited
- Charities Aid Foundation, USA
- Pattabiraman R
- Hyundai Transys Lear Automotive India Private Ltd
- Heat and Control South Asia Pvt Ltd
- Trichur Sundaram Santhanam & Family Private Ltd
- IIT Madras Research Park
- City Union Bank Limited
- IGP Engineers Pvt Ltd
- GRT Jewellers India Pvt Ltd
- Bharathram Vijayaraghavan
- Yoga Vidhya Pranic Healing Foundation of Tamilnadu
- Meenakshi India Limited
- Padmini A
- Srivats Ram
- The Sanmar Group CSR Trust
- Urjita Electronics Pvt Ltd
- Embedur Systems (India) Private Limited
- FLYJAC Logistics Pvt Ltd

Powered by Volunteer Spirit

Volunteering is about giving back, offering support and making a meaningful difference in the lives of others. More than 30 volunteers joined this year, bringing their time, skills and compassion to support patients, families and the Institute's work. Our volunteer community includes cancer survivors and those who serve in memory of loved ones, with members from diverse backgrounds such as teachers, homemakers, ex-servicemen, bankers, artists and software professionals. Many have been associated with the Institute for over 25 years, reflecting a deep and enduring commitment to service.


Financial Overview 2025-26

M/s. R. Janakiraman & Co - Approved Auditors



Source Of Funds

- 59% Hospital Income
- 27% Grants and Donations
- 10% Interest
- 4% Other Income



Utilisation Of Funds

- 78% Establishment Cost, Patient Facility Cost, Maintenance, Utilities etc.
- 22% Capital Expenditure and Investments

Care Enabling Services

Our dedicated care enabling service teams are highly specialised and ensure smooth and efficient day-to-day operations. Working behind the scenes, they empower our healthcare professionals to provide comprehensive and compassionate cancer care to everyone.

Support services include ▼

- Biomedical Engineering
- Central Sterile Supply Department
- Communications
- Dietetics
- Facility Management
- Finance, Accounts, Insurance & Cash
- Gas Plant
- Human Resources
- Library
- Linen Management
- Medical Stores
- OPD & Ward Secretaries
- Purchase
- Quality

Displays of drawings and paintings created by young patients undergoing cancer treatment in the Mahesh Memorial Trust Paediatric Ward as part of therapeutic art programs organised throughout the year.





Editorial Team

Cancer Institute (WIA) - **Smt. S. Ajitha, Smt. Gayatri Ravindran**

RxStory - **Mr. Arvind Suresh**

SCAN TO DONATE

cancerinstitutewia.in/donations

@CI_WIA | @cancerinstitute_wia | @cancer-institute-wia

@cancerinstitutechennai2012 | @Cancerinstitutewiaadyarchennai

Dr. V. Shanta Campus
No. 1, Canal Bank Road, Gandhi Nagar, Adyar, Chennai – 600 020

044 - 24910754 / 24911526

https://cancerinstitutewia.in

Dr. S. Krishnamurthi Campus
No. 38, Sardar Patel Road, Chennai – 600 036

044 - 22209150

9500309150 (WhatsApp)

DESIGNED BY

RxStory, Chennai, INDIA

rxstory.in | 7418333485